Marc Lemonnier retweeted
⚡️ Great panel on the value of antibiotics.
We need ABs able to address the highest unmet medical needs and strong translational teams.
@AMRActionFund @AllianceBEAM
#AMR – at Basel-City, Switzerland
Marc Lemonnier retweeted
ANTABIO Raises €25 million in Series B Financing. The financing will be used to support the clinical development of MEM-ANT3310, a next generation antibacterial combination currently in phase 1 trials b3cnewswire.com/202312122501… #biotech
Marc Lemonnier retweeted
French drugmaker receives funding for combination antibiotic
Antabio announced that it raised $25 million in financing to complete phase 2 research on its antibiotic/beta-lactamase inhibitor combination.
ow.ly/2ig950Qi3ns
Marc Lemonnier retweeted
We are thrilled to welcome @antabio to our portfolio. Learn more about the company's €25 million Series B round: antabio.com/2023/12/12/antab… #AMR
Marc Lemonnier retweeted
#Toulouse - #Santé : Antabio boucle une série B majeure pour commercialiser son premier traitement toulouse.latribune.fr/entrep… via @LaTribuneTlse @LaTribune
Marc Lemonnier retweeted
Intervention ensuite inspirante de Marc Lemonnier de @antabio sur une idée séduisante : faire un "Healthbus" toulousain en explorant un modèle multi partenarial public-privé comme sur ARPEGE
Complété dans le même sens par le directeur de @IUCTOncopole
autour du décloisonnement 8/
Très peiné par cette nouvelle. P-O G était toujours prêt à aider les biotechs françaises, toujours à l'écoute. Au nom d'@antabio, condoléances à sa famille et à ses proches.
Sous le choc du décès de Pierre-Olivier Goineau, j’adresse toutes mes condoléances à sa famille, ses proches et à ses amis. J’ai côtoyé plusieurs années POG au sein du CA de @FranceBiotech, c’était une belle personnalité, bienveillante et attachante, repose en paix POG. 🕊️
The start of our first in man study for MEM-ANT3310 marks a significant milestone for @antabio as we transition to becoming a clinical stage biotechnology company.
Today my warm gratitude goes to my colleagues at @antabio for their excellent work and continuous dedication.
#AMR
@antabio announces dosing of the first subjects in its Phase 1 clinical trial of MEM-ANT3310, a next generation treatment of hospital infections caused by carbapenem-resistant Acinetobacter baumannii (#CRAB) and carbapenem-resistant Enterobacterales (#CRE)
shorturl.at/gkovS
Marc Lemonnier retweeted
Our first-place #ECCMID2023 Art Gallery winner is Ana Pelivan (Croatia) who won with her painting titled "Cause of Death" showcasing the fight against multidrug-resistant pathogens is difficult, and the most devastating feeling is losing a patient because of them. #ECCMIDart
Marc Lemonnier retweeted
Check our new paper on the chemical optimization & initial evaluation in cellular & animal models of @antabio's #Pseudomonas #aeruginosa #LasB inhibitors.
An international collaboration based on a work initially funded by @wellcometrust & @CARB_X
pubs.acs.org/doi/10.1021/acs…
Marc Lemonnier retweeted
3⃣Revenues from new antimicrobials do not recoup R&D investments.
As long as this equation is out of balance, it is impossible to have a fully functioning innovation engine.
➡️This is why a PULL mechanism should be of sufficient magnitude to bring things back into balance.
Marc Lemonnier retweeted
2⃣The biotech ecosystem is committed to developing new products, but #SMEs struggle to raise💰to fight #AMR
SMEs' survival is often measured in months which discourages talented👩🔬
⚠️Rapid action is urgently needed for a PULL mechanism to preserve this ecosystem and help it thrive
Marc Lemonnier retweeted
Tomorrow kicks off #WAAW2022, so let's remember what's at stake. Next year will be critical in shaping tomorrow's innovation, with the #EU reshaping the pharmaceutical regulatory landscape. The future of #SMEs depends on it. Our future depends on it. bit.ly/AMRfuture
A pivotal report from our partners at #ARPEGE @TSEinfo on how Transferable Exclusivity Vouchers can be an effective mechanism for rewarding innovation and revitalizing the #AMR market. 👇
A new policy paper by Pierre Dubois, Paul-Henri Moisson & #JeanTirole focused on the mechanisms & levers to be used to encourage innovation in the #AntimicrobialResistance sector. #ARPEGE_AMR
👉 tse-fr.eu/health-policy-work…
Marc Lemonnier retweeted
BEAM signed a Call to Action to #G20 Leaders, Health and Finance Ministers. Take a look at the recommendations focusing on #AMR and help us spread the word to tackle AMR globally! h20annualsummit.com/call-to-…
Marc Lemonnier retweeted
Great discussion today at the scientific symposium organized in the frame of the @Europe2022FR and dedicated to #antimicrobialresistance. The panel moderated by Marc Lemonnier and Christine Ardal showcased the options for incentivising innovation and what is at stake.
Marc Lemonnier retweeted
The #EU Pharma Legislation revision is on the horizon. What solutions do #SMEs need from our policymakers to unlock the innovation potential to tackle #AMR? Check out this video and don’t hesitate to spread the voice of SMEs too: like, share, and comment! bit.ly/3K057dv
Marc Lemonnier retweeted
4 Pillars in Focus: 80% of the global AMR product pipeline is held by SMEs. In order to #2 unlock the innovation potential embedded in this portfolio, the market needs to be more predictable to convince investors.
